Difference between revisions of "Major Histocompatability Complexes"
Jump to navigation
Jump to search
| Line 10: | Line 10: | ||
}} | }} | ||
| − | = | + | =Classes= |
| + | ==MHC I== | ||
===Structure=== | ===Structure=== | ||
| − | + | * MHC class I is expressed on virtually all nucleated cells | |
| − | * MHC class I is expressed on virtually all nucleated cells | + | * MHC class I consists of a membrane-associated heavy chain bound non-covalently with a secreted light chain |
| − | * MHC class I consists of a membrane-associated heavy chain bound non-covalently with a secreted light chain | ||
** Heavy chain: | ** Heavy chain: | ||
| − | *** Made up of three distinct extracellular protein domains | + | *** Made up of three distinct extracellular protein domains |
| − | **** α1, α2 and α3 | + | **** α1, α2 and α3 |
| − | *** The C- terminus is cytoplasmic | + | *** The C- terminus is cytoplasmic |
** Light chain: | ** Light chain: | ||
| − | *** Known as β2-microglobulin | + | *** Known as β2-microglobulin |
| − | *** Similar in structure to one of the heavy chain domains | + | *** Similar in structure to one of the heavy chain domains |
| − | *** Not membrane associated | + | *** Not membrane associated |
| − | **** But binds to the α3-domain of the heavy chain | + | **** But binds to the α3-domain of the heavy chain |
| − | * The MHC class I domains are structurally and genetically related to immunoglobulin and TcR domains | + | * The MHC class I domains are structurally and genetically related to immunoglobulin and TcR domains |
| − | ** The outer domains (α1 and α2) are like the variable domains | + | ** The outer domains (α1 and α2) are like the variable domains |
| − | ** The α3 domain and β2m are like thrconstant domains | + | ** The α3 domain and β2m are like thrconstant domains |
| − | * MHC class I molecules are folded to form specific 3-dimensional structures | + | * MHC class I molecules are folded to form specific 3-dimensional structures |
| − | ** The α1 and α2 domains are folded to produce an antigen-binding groove | + | ** The α1 and α2 domains are folded to produce an antigen-binding groove |
| − | *** This groove can bind molecules of a limited size only | + | *** This groove can bind molecules of a limited size only (8-10 amino acids) |
| − | + | **** This limits the size of epitope seen by the T-cell receptors | |
| − | **** This limits the size of epitope seen by the T-cell receptors | ||
===Function=== | ===Function=== | ||
| + | * MHC class I molecules bind antigenic peptides derived from within the cell and present these to the T-cell receptors of '''CD8+ T-cells''' | ||
| + | ** E.g. virus-encoded antigen | ||
| + | * Endogenously produced proteins are produced in the cell cytoplasm | ||
| + | ** Intracellular pathogens utilise this cellular metabolic machinery for protein synthesis | ||
| + | ** Many of the proteins synthesised are not used and are re-utilised by the cell | ||
| + | *** Peptides from these proteins are transported to the Golgi apparatus by specific transporter molecules | ||
| + | *** These peptides then interact with newly synthesized MHC class I molecules. | ||
| + | * Only MHC class I that is associated with peptide will be expressed at the surface | ||
| + | ** The immune system is therefore able to see antigen from intracleeular pathogens | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| + | ==MHC II== | ||
===Structure=== | ===Structure=== | ||
| − | + | * MHC class II is expressed mainly on '''macrophages''', '''dendritic cells''' and '''B-lymphocytes''' | |
| − | * MHC class II is expressed mainly on macrophages, dendritic cells and B-lymphocytes | + | * MHC class II consists of membrane-associated α and β chains |
| − | * MHC class II consists of membrane-associated α and β chains | + | ** Each chain is a transmembrane glycoprotein |
| − | ** Each chain is a transmembrane glycoprotein | + | ** The extracellular parts of each chain have two Ig-like domains |
| − | ** The extracellular parts of each chain have two Ig-like domains | + | *** α1 and 7alpha;2, β1 and β2 |
| − | *** α1 and 7alpha;2, β1 and β2 | + | **** The outer domains (α1 and β1) are variable-like |
| − | **** The outer domains (α1 and β1) are variable-like | + | **** The inner domains (α2 and β2) are constant-like |
| − | **** The inner domains (α2 and β2) are constant-like | + | * The 3-dimensional structure of MHC class II is similar to MHC class I |
| − | * The 3-dimensional structure of MHC class II is similar to MHC class I | + | ** The outer domains of the α and β chains fold in a similar way to the α1 and α2 domains of class I |
| − | ** The outer domains of the α and β chains fold in a similar way to the α1 and α2 domains of class I | + | *** Produce the antigen-binding groove |
| − | *** Produce the antigen-binding groove | ||
===Function=== | ===Function=== | ||
| − | + | * MHC class II molecules bind antigenic peptides and present them to TCR on CD4+ T-cells | |
| − | * MHC class II molecules bind antigenic peptides and present them to | + | * The antigen-binding groove is larger and more open than that of MHC class I |
| − | * The antigen-binding groove is larger and more open than that of MHC class I | + | ** MHC II can therefore interact with larger peptides |
| − | ** MHC II can therefore interact with larger peptides | + | * MHC class II are present on those cells that have antigen-processing ability |
| − | * MHC class II are present on those cells that have antigen-processing ability | + | ** Interact with antigenic peptides originating from an extracellular source |
| − | ** Interact with antigenic peptides originating from an extracellular source | + | * After synthesis, MHC class II molecules are transported into special endosomes |
| − | * After synthesis, MHC class II molecules are transported into special endosomes | + | ** These endosomes fuse with lysosomes that contain the digested remnants of phagocytosed microorganisms |
| − | ** These endosomes fuse with lysosomes that contain the digested remnants of phagocytosed microorganisms | + | *** The peptides from the lysosome interact with the MHC class II molecules |
| − | *** The peptides from the lysosome interact with the MHC class II molecules | + | **** The peptide-MHC class II complex gets transported to the cell surface |
| − | **** The peptide-MHC class II complex gets transported to the cell surface | ||
==Interaction of MHC With Antigen== | ==Interaction of MHC With Antigen== | ||
| + | * The MHC molecules do not recognise specific amino acid sequences of antigens | ||
| + | ** Instead, they recognise particular motifs of amino acids | ||
| + | * The association of any MHC allele with a peptide may be determined by the presence of as few as two amino acids | ||
| + | ** However, these determinants must be present within a particular array | ||
| + | * The actual identity of the amino acids in not important for MHC binding | ||
| + | ** Instead, the physical and chemical characteristics of the amino acid are vital | ||
| + | * Interactions of individual amino acids at the head and tail of the peptide-binding groove control the binding of peptides | ||
| + | ** Are mainly positioned at the floor of the antigen-binding groove, or within the helices facing into the groove | ||
| + | ** These MHC amino acids associate with amino acids near the ends of the peptides | ||
| + | *** The intervening stretch of peptide folds into a helix within the groove | ||
| + | *** Is the target for T cell receptor recognition | ||
| − | + | ===TCR-MHC Interaction=== | |
| − | + | * Only peptide associated with self-MHC will interact with and activate T-cells | |
| − | + | ** T-cells cannot be activated by a peptide on a foreign cell | |
| − | + | ** T-cells will react against foreign MHC molecules | |
| − | + | *** This is the basis of graft rejection | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | === | ||
| − | |||
| − | * Only peptide associated with self-MHC will interact with and activate T-cells | ||
| − | ** T-cells cannot be activated by a peptide on a foreign cell | ||
| − | ** T-cells will react against foreign MHC molecules | ||
| − | *** This is the basis of graft rejection | ||
===The Genetics of the MHC=== | ===The Genetics of the MHC=== | ||
| − | + | * Different individuals have different critical amino acids within the MHC | |
| − | * Different individuals have different critical amino acids within the MHC | + | ** I.e. different amino acids that determine peptide binding |
| − | ** I.e. different amino acids that determine peptide binding | + | ** This variation is termed '''MHC polymorphism''' |
| − | ** This variation is termed '''MHC polymorphism''' | + | * There are millions of variations in antibodies and TCR |
| − | * There are millions of variations in antibodies and | + | ** However, with MHC there is very limited variation between molecules |
| − | ** However, with MHC there is very limited variation between molecules | + | * MHC polymorphism has been best studied in the human |
| − | * MHC polymorphism has been best studied in the human | ||
===In the Human=== | ===In the Human=== | ||
| − | |||
* Humans express: | * Humans express: | ||
| − | ** Three types (loci) of MHC class I molecules | + | ** Three types (loci) of MHC class I molecules |
| − | *** HLA (Human Leukocyte Antigen)- A, B, and C | + | *** HLA (Human Leukocyte Antigen)- A, B, and C |
| − | ** Three loci of MHC class II molecules | + | ** Three loci of MHC class II molecules |
| − | *** HLA-DP, DQ and DR | + | *** HLA-DP, DQ and DR |
| − | * In the entire human population there are only approximately 50 different variants (alleles) at each MHC class I and class II locus | + | * In the entire human population there are only approximately 50 different variants (alleles) at each MHC class I and class II locus |
| − | ** The variation within MHC class I is entirely on the class I heavy chain | + | ** The variation within MHC class I is entirely on the class I heavy chain |
| − | *** The β2m is invariant | + | *** The β2m is invariant |
| − | ** The variation within MHC class II is mainly within the β chains | + | ** The variation within MHC class II is mainly within the β chains |
| − | * Every individual has two alleles at each MHC locus | + | * Every individual has two alleles at each MHC locus |
| − | ** One inherited from each parent | + | ** One inherited from each parent |
| − | ** Any individual will therfore express two variants at most at each locus | + | ** Any individual will therfore express two variants at most at each locus |
*** This gives a maximum variability for an individual of: | *** This gives a maximum variability for an individual of: | ||
| − | **** 6 different variants of MHC class I | + | **** 6 different variants of MHC class I |
| − | ***** 2 each of HLA- A, B and C | + | ***** 2 each of HLA- A, B and C |
| − | **** 6 different variants of MHC class II | + | **** 6 different variants of MHC class II |
| − | ***** 2 each of HLA- DP, DQ and DR | + | ***** 2 each of HLA- DP, DQ and DR |
| − | * Many animal species have fewer loci than the human | + | * Many animal species have fewer loci than the human |
| − | ** E.g. ruminants have no MHC class II DP | + | ** E.g. ruminants have no MHC class II DP |
===MHC and Disease=== | ===MHC and Disease=== | ||
| − | + | * Antigen from a pathogen has to be seen by the host MHC before an efficient immune response can occur | |
| − | * Antigen from a pathogen has to be seen by the host MHC before an efficient immune response can occur | + | ** There is therefore a constant evolutionary battle between the host and the pathogen |
| − | ** There is therefore a constant evolutionary battle between the host and the pathogen | + | *** There is selective pressure on the pathogen to evolve proteins that do not interact with the host MHC |
| − | *** There is selective pressure on the pathogen to evolve proteins that do not interact with the host MHC | + | *** There is selective pressure on the host to continue to recognize the pathogen |
| − | *** There is selective pressure on the host to continue to recognize the pathogen | ||
* The consequence of this parallel evolution is that host-pathogen relationships can lead to the selection of particular MHC variants, for example: | * The consequence of this parallel evolution is that host-pathogen relationships can lead to the selection of particular MHC variants, for example: | ||
| − | ** MHC class II alleles DR13/DR1*1301 are prevalent in Central and Western Africa | + | ** MHC class II alleles DR13/DR1*1301 are prevalent in Central and Western Africa |
| − | *** Impart resistance to malaria | + | *** Impart resistance to malaria |
| − | ** MHC-DRB1 is prevalent in Western Europe, but rare in the Inuit populations of North America | + | ** MHC-DRB1 is prevalent in Western Europe, but rare in the Inuit populations of North America |
| − | *** Associated with the clearance of hepatitis B infection in Western Europe | + | *** Associated with the clearance of hepatitis B infection in Western Europe |
| − | *** Inuits have the highest incidence of hepatitis B in the world | + | *** Inuits have the highest incidence of hepatitis B in the world |
** In humans there are also strong associations between certain alleles and some autoimmune diseases, for example: | ** In humans there are also strong associations between certain alleles and some autoimmune diseases, for example: | ||
| − | *** Diabetes mellitus | + | *** Diabetes mellitus |
| − | *** Ankylosing spondylitis | + | *** Ankylosing spondylitis |
| − | *** Rheumatoid arthritis | + | *** Rheumatoid arthritis |
Revision as of 15:14, 28 August 2008
|
|
Classes
MHC I
Structure
- MHC class I is expressed on virtually all nucleated cells
- MHC class I consists of a membrane-associated heavy chain bound non-covalently with a secreted light chain
- Heavy chain:
- Made up of three distinct extracellular protein domains
- α1, α2 and α3
- The C- terminus is cytoplasmic
- Made up of three distinct extracellular protein domains
- Light chain:
- Known as β2-microglobulin
- Similar in structure to one of the heavy chain domains
- Not membrane associated
- But binds to the α3-domain of the heavy chain
- Heavy chain:
- The MHC class I domains are structurally and genetically related to immunoglobulin and TcR domains
- The outer domains (α1 and α2) are like the variable domains
- The α3 domain and β2m are like thrconstant domains
- MHC class I molecules are folded to form specific 3-dimensional structures
- The α1 and α2 domains are folded to produce an antigen-binding groove
- This groove can bind molecules of a limited size only (8-10 amino acids)
- This limits the size of epitope seen by the T-cell receptors
- This groove can bind molecules of a limited size only (8-10 amino acids)
- The α1 and α2 domains are folded to produce an antigen-binding groove
Function
- MHC class I molecules bind antigenic peptides derived from within the cell and present these to the T-cell receptors of CD8+ T-cells
- E.g. virus-encoded antigen
- Endogenously produced proteins are produced in the cell cytoplasm
- Intracellular pathogens utilise this cellular metabolic machinery for protein synthesis
- Many of the proteins synthesised are not used and are re-utilised by the cell
- Peptides from these proteins are transported to the Golgi apparatus by specific transporter molecules
- These peptides then interact with newly synthesized MHC class I molecules.
- Only MHC class I that is associated with peptide will be expressed at the surface
- The immune system is therefore able to see antigen from intracleeular pathogens
MHC II
Structure
- MHC class II is expressed mainly on macrophages, dendritic cells and B-lymphocytes
- MHC class II consists of membrane-associated α and β chains
- Each chain is a transmembrane glycoprotein
- The extracellular parts of each chain have two Ig-like domains
- α1 and 7alpha;2, β1 and β2
- The outer domains (α1 and β1) are variable-like
- The inner domains (α2 and β2) are constant-like
- α1 and 7alpha;2, β1 and β2
- The 3-dimensional structure of MHC class II is similar to MHC class I
- The outer domains of the α and β chains fold in a similar way to the α1 and α2 domains of class I
- Produce the antigen-binding groove
- The outer domains of the α and β chains fold in a similar way to the α1 and α2 domains of class I
Function
- MHC class II molecules bind antigenic peptides and present them to TCR on CD4+ T-cells
- The antigen-binding groove is larger and more open than that of MHC class I
- MHC II can therefore interact with larger peptides
- MHC class II are present on those cells that have antigen-processing ability
- Interact with antigenic peptides originating from an extracellular source
- After synthesis, MHC class II molecules are transported into special endosomes
- These endosomes fuse with lysosomes that contain the digested remnants of phagocytosed microorganisms
- The peptides from the lysosome interact with the MHC class II molecules
- The peptide-MHC class II complex gets transported to the cell surface
- The peptides from the lysosome interact with the MHC class II molecules
- These endosomes fuse with lysosomes that contain the digested remnants of phagocytosed microorganisms
Interaction of MHC With Antigen
- The MHC molecules do not recognise specific amino acid sequences of antigens
- Instead, they recognise particular motifs of amino acids
- The association of any MHC allele with a peptide may be determined by the presence of as few as two amino acids
- However, these determinants must be present within a particular array
- The actual identity of the amino acids in not important for MHC binding
- Instead, the physical and chemical characteristics of the amino acid are vital
- Interactions of individual amino acids at the head and tail of the peptide-binding groove control the binding of peptides
- Are mainly positioned at the floor of the antigen-binding groove, or within the helices facing into the groove
- These MHC amino acids associate with amino acids near the ends of the peptides
- The intervening stretch of peptide folds into a helix within the groove
- Is the target for T cell receptor recognition
TCR-MHC Interaction
- Only peptide associated with self-MHC will interact with and activate T-cells
- T-cells cannot be activated by a peptide on a foreign cell
- T-cells will react against foreign MHC molecules
- This is the basis of graft rejection
The Genetics of the MHC
- Different individuals have different critical amino acids within the MHC
- I.e. different amino acids that determine peptide binding
- This variation is termed MHC polymorphism
- There are millions of variations in antibodies and TCR
- However, with MHC there is very limited variation between molecules
- MHC polymorphism has been best studied in the human
In the Human
- Humans express:
- Three types (loci) of MHC class I molecules
- HLA (Human Leukocyte Antigen)- A, B, and C
- Three loci of MHC class II molecules
- HLA-DP, DQ and DR
- Three types (loci) of MHC class I molecules
- In the entire human population there are only approximately 50 different variants (alleles) at each MHC class I and class II locus
- The variation within MHC class I is entirely on the class I heavy chain
- The β2m is invariant
- The variation within MHC class II is mainly within the β chains
- The variation within MHC class I is entirely on the class I heavy chain
- Every individual has two alleles at each MHC locus
- One inherited from each parent
- Any individual will therfore express two variants at most at each locus
- This gives a maximum variability for an individual of:
- 6 different variants of MHC class I
- 2 each of HLA- A, B and C
- 6 different variants of MHC class II
- 2 each of HLA- DP, DQ and DR
- 6 different variants of MHC class I
- This gives a maximum variability for an individual of:
- Many animal species have fewer loci than the human
- E.g. ruminants have no MHC class II DP
MHC and Disease
- Antigen from a pathogen has to be seen by the host MHC before an efficient immune response can occur
- There is therefore a constant evolutionary battle between the host and the pathogen
- There is selective pressure on the pathogen to evolve proteins that do not interact with the host MHC
- There is selective pressure on the host to continue to recognize the pathogen
- There is therefore a constant evolutionary battle between the host and the pathogen
- The consequence of this parallel evolution is that host-pathogen relationships can lead to the selection of particular MHC variants, for example:
- MHC class II alleles DR13/DR1*1301 are prevalent in Central and Western Africa
- Impart resistance to malaria
- MHC-DRB1 is prevalent in Western Europe, but rare in the Inuit populations of North America
- Associated with the clearance of hepatitis B infection in Western Europe
- Inuits have the highest incidence of hepatitis B in the world
- In humans there are also strong associations between certain alleles and some autoimmune diseases, for example:
- Diabetes mellitus
- Ankylosing spondylitis
- Rheumatoid arthritis
- MHC class II alleles DR13/DR1*1301 are prevalent in Central and Western Africa